PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease?

Abstract

This commentary is primarily devoted to a recent observational study by Mantovani and colleagues (Aliment Pharmacol Ther. 2023; 57: 1093-102) examining the adverse effect of the patatin-like phospholipase domain-containing protein-3 (PNPLA3) rs738409 G allele on the kidney function in a cohort of 1,144 middle-aged Italian individuals with metabolic dysfunction. In this study, the authors found that the PNPLA3 rs738409 G allele was significantly associated with lower levels of estimated glomerular filtrate rate (eGFR), even after adjusting for not only common anthropometric and cardiometabolic risk factors but also ethnicity, serum liver enzymes, use of drugs against dyslipidemia and chronic kidney disease polygenic risk score. Additionally, in a subgroup of 144 patients followed for a median of 17 months, the authors also found that the PNPLA3 rs738409 G allele was independently associated with a faster eGFR decline. Commenting on the cohort study by Mantovani et al., we also summarized the rapidly expanding evidence linking the PNPLA3 rs738409 variant with the risk of kidney disease. Furthermore, we discussed the potential research implications of these findings.

Keywords

Nonalcoholic fatty liver disease / nonalcoholic steatohepatitis / glomerular filtration rate / kidney function / chronic kidney disease / PNPLA3 rs738409

References

[1] Pingitore P.The role of PNPLA3 in health and disease.Biochim Biophys Acta Mol Cell Biol Lipids2019;1864:900-6

[2] Eslam M,Romeo S.Genetics and epigenetics of NAFLD and NASH: clinical impact.J Hepatol2018;68:268-79

[3] Romeo S,Xing C.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2008;40:1461-5. PMCID:PMC2597056

[4] Anstee QM,Cockell S.EPoS Consortium InvestigatorsGenome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort.J Hepatol2020;73:505-15

[5] Oniki K,Izuka T.Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects.PLoS One2015;10:e0132640 PMCID:PMC4511733

[6] Musso G,Gambino R.PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease.Hepatology2015;62:658-9

[7] Mantovani A,Sani E.Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease.Diabetes Metab2019;45:480-7.

[8] Targher G,Alisi A.Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD.Hepatology2019;70:142-53

[9] Marzuillo P,Guarino S.Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity.Pediatr Obes2019;14:e12539

[10] Sun DQ,Xu G.PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels.Liver Int2020;40:107-19

[11] Mantovani A,Zusi C.PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings.Liver Int2020;40:1130-41

[12] Mantovani A,Csermely A.Association between PNPLA3 rs738409 variant and 5-year estimated glomerular filtration rate decline in post-menopausal women with type 2 diabetes: A panel-data analysis.Nutr Metab Cardiovasc Dis2023;33:1093-7.

[13] Mantovani A,Margarita S.Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction.Aliment Pharmacol Ther2023;57:1093-102

[14] Liu J,Wang S.Metabolic disorders induced by PNPLA3 and TM6SF2 gene variants affect chronic kidney disease in patients infected with non-genotype 3 hepatitis C virus.Lipids Health Dis2023;22:91 PMCID:PMC10316563

[15] Koo BK,Joo SK.Association between a polymorphism in MBOAT7 and chronic kidney disease in patients with biopsy-confirmed nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2020;18:2837-9.e2.

[16] Baratta F,Di Costanzo A.Metabolic syndrome but not fatty liver-associated genetic variants correlates with glomerular renal function decline in patients with non-alcoholic fatty liver disease.Biomedicines2022;10:720 PMCID:PMC8944982

[17] Di Costanzo A,D'Erasmo L.Nonalcoholic fatty liver disease (NAFLD), but not its susceptibility gene variants, influences the decrease of kidney function in overweight/obese children.Int J Mol Sci2019;20:4444 PMCID:PMC6769859

[18] Khan A,Patki A.Genome-wide polygenic score to predict chronic kidney disease across ancestries.Nat Med2022;28:1412-20 PMCID:PMC9329233

[19] Sun DQ,Byrne CD.An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.Hepatobiliary Surg Nutr2023;12:386-403 PMCID:PMC10282675

[20] Barata L,Bielak LF.Insulin resistance exacerbates genetic predisposition to nonalcoholic fatty liver disease in individuals without diabetes.Hepatol Commun2019;3:894-907 PMCID:PMC6601321

[21] Mallela SK,Ducasa GM,Fornoni A.Detection and Quantification of Lipid Droplets in Differentiated Human Podocytes.Methods Mol Biol2019;1996:199-296 PMCID:PMC7941729

[22] Mantovani A,Dalbeni A,Buzzetti E.Risk of kidney dysfunction in nafld.Curr Pharm Des2020;26:1045-61

[23] Wang TY,Bu ZY.Association of metabolic dysfunction-associated fatty liver disease with kidney disease.Nat Rev Nephrol2022;18:259-68.

[24] Pirola CJ.Editorial: NAFLD, chronic kidney disease, and pleiotropy-why is PNPLA3 omnipresent?.Aliment Pharmacol Ther2023;57:1180-2.

[25] Lonardo A,Targher G.Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications.Int J Mol Sci2022;23:13320 PMCID:PMC9654863

[26] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2022;71:156-62.

[27] Targher G.Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.Nat Rev Nephrol2017;13:297-310

[28] Lonardo A,Osna N.Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.Metab Target Organ Damage2022;2:12 PMCID:PMC9453927